Logo image of ATHE

ALTERITY THERAPEUTICS-ADR (ATHE) Stock Price, Forecast & Analysis

USA - NASDAQ:ATHE - US02155X2053 - ADR

3.7899 USD
+0.12 (+3.27%)
Last: 11/12/2025, 8:00:01 PM

ATHE Key Statistics, Chart & Performance

Key Statistics
Market Cap68.69M
Revenue(TTM)446.30K
Net Income(TTM)-12.15M
Shares18.13M
Float17.20M
52 Week High7
52 Week Low1
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.58
PEN/A
Fwd PEN/A
Earnings (Next)02-26 2026-02-26
IPO2000-03-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ATHE short term performance overview.The bars show the price performance of ATHE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

ATHE long term performance overview.The bars show the price performance of ATHE in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of ATHE is 3.7899 USD. In the past month the price decreased by -24.35%. In the past year, price increased by 242.98%.

ALTERITY THERAPEUTICS-ADR / ATHE Daily stock chart

ATHE Latest News, Press Relases and Analysis

ATHE Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 24.68 412.01B
AMGN AMGEN INC 15.38 181.04B
GILD GILEAD SCIENCES INC 15.07 153.12B
VRTX VERTEX PHARMACEUTICALS INC 25.01 111.32B
REGN REGENERON PHARMACEUTICALS 15.15 72.26B
ALNY ALNYLAM PHARMACEUTICALS INC 887.73 59.35B
INSM INSMED INC N/A 41.09B
NTRA NATERA INC N/A 28.75B
BIIB BIOGEN INC 9.65 23.67B
INCY INCYTE CORP 16.86 21.14B
UTHR UNITED THERAPEUTICS CORP 17.49 20.88B
NBIX NEUROCRINE BIOSCIENCES INC 35.13 14.56B

About ATHE

Company Profile

ATHE logo image Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Company Info

ALTERITY THERAPEUTICS-ADR

Level 14, 350 Collins Street

Melbourne VICTORIA VIC 3000 AU

CEO: David A. Stamler

Employees: 9

ATHE Company Website

ATHE Investor Relations

Phone: 61393494906

ALTERITY THERAPEUTICS-ADR / ATHE FAQ

What does ATHE do?

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.


What is the current price of ATHE stock?

The current stock price of ATHE is 3.7899 USD. The price increased by 3.27% in the last trading session.


Does ATHE stock pay dividends?

ATHE does not pay a dividend.


How is the ChartMill rating for ALTERITY THERAPEUTICS-ADR?

ATHE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


How many employees does ALTERITY THERAPEUTICS-ADR have?

ALTERITY THERAPEUTICS-ADR (ATHE) currently has 9 employees.


Can you provide the upcoming earnings date for ALTERITY THERAPEUTICS-ADR?

ALTERITY THERAPEUTICS-ADR (ATHE) will report earnings on 2026-02-26.


What is the ownership structure of ALTERITY THERAPEUTICS-ADR (ATHE)?

You can find the ownership structure of ALTERITY THERAPEUTICS-ADR (ATHE) on the Ownership tab.


ATHE Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to ATHE. When comparing the yearly performance of all stocks, ATHE is one of the better performing stocks in the market, outperforming 96.78% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ATHE Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ATHE. ATHE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ATHE Financial Highlights

Over the last trailing twelve months ATHE reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 59.62% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -26.39%
ROE -28.65%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%73.08%
Sales Q2Q%123.33%
EPS 1Y (TTM)59.62%
Revenue 1Y (TTM)66.28%

ATHE Forecast & Estimates

For the next year, analysts expect an EPS growth of 100% and a revenue growth 1302.63% for ATHE


Analysts
Analysts100
Price TargetN/A
EPS Next Y100%
Revenue Next Year1302.63%

ATHE Ownership

Ownership
Inst Owners14.13%
Ins Owners2.39%
Short Float %0.76%
Short Ratio1.21